| Literature DB >> 25863251 |
Jasmine A Luzum1, Joseph P Kitzmiller2, Paul J Isackson3, Changxing Ma4, Marisa W Medina5, Anees M Dauki6, Eduard B Mikulik2, Heather M Ochs-Balcom7, Georgirene D Vladutiu8.
Abstract
Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine amidinotransferase (GATM rs9806699 G > A) was previously associated with reduced risk for SIM. Our objective was to replicate the GATM association in a large, multicenter SIM case-control study. Mild and severe SIM cases and age- and gender-matched controls were enrolled. Participants were genotyped, and associations were tested (n = 715) using chi-square and logistic regression with consideration for SIM severity and exclusion of subjects with potentially confounding comedications. The minor allele (A) frequencies of GATM rs9806699 in the controls (n = 106), mild SIM (n = 324), and severe SIM (n = 285) cases were 0.26, 0.28, and 0.29, respectively (p = 0.447). The unadjusted odds ratio for the A allele for any SIM (mild or severe) was 1.14 (0.82-1.61; p = 0.437), which remained nonsignificant in all models. Our results do not replicate the association between GATM rs9806699 and SIM.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25863251 PMCID： PMC4394188 DOI： 10.1016/j.cmet.2015.03.003
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287